Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients
Status:
Withdrawn
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This research study is a prospective, randomized, blinded, placebo controlled trial
evaluating the benefit of IV acetaminophen (Ofirmev™) as adjuvant analgesia in geriatric hip
fracture patients. IV acetaminophen has received FDA approval. IV acetaminophen does not have
the liver toxicity as oral acetaminophen. No oral acetaminophen will be administered. All
patients diagnosed with a hip fracture aged at least 65 years and expected to undergo
surgical intervention are eligible to participate. Hip fractures affect greater than 300,000
geriatric patients annually, representing the second leading cause of hospitalization for
this patient population. Pain control in these patients is often problematic due to
co-morbidities and changes in their pharmacokinetic and pharmacodynamic profiles. Subjects
may receive the normal DVT prophylactic treatments post-op.